Health-related quality of life results from the phase III CheckMate 067 study
Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demon...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Schadendorf, Dirk [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study - Hamzah, N. ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:82 ; year:2017 ; pages:80-91 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejca.2017.05.031 |
|---|
| Katalog-ID: |
ELV020442440 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV020442440 | ||
| 003 | DE-627 | ||
| 005 | 20230625131840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.05.031 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017016000016.pica |
| 035 | |a (DE-627)ELV020442440 | ||
| 035 | |a (ELSEVIER)S0959-8049(17)30995-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Schadendorf, Dirk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life results from the phase III CheckMate 067 study |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. | ||
| 520 | |a Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. | ||
| 650 | 7 | |a Health-related quality of life |2 Elsevier | |
| 650 | 7 | |a Checkpoint inhibitors |2 Elsevier | |
| 650 | 7 | |a Nivolumab |2 Elsevier | |
| 650 | 7 | |a Ipilimumab |2 Elsevier | |
| 650 | 7 | |a Advanced melanoma |2 Elsevier | |
| 700 | 1 | |a Larkin, James |4 oth | |
| 700 | 1 | |a Wolchok, Jedd |4 oth | |
| 700 | 1 | |a Hodi, F. Stephen |4 oth | |
| 700 | 1 | |a Chiarion-Sileni, Vanna |4 oth | |
| 700 | 1 | |a Gonzalez, Rene |4 oth | |
| 700 | 1 | |a Rutkowski, Piotr |4 oth | |
| 700 | 1 | |a Grob, Jean-Jacques |4 oth | |
| 700 | 1 | |a Cowey, C. Lance |4 oth | |
| 700 | 1 | |a Lao, Christopher |4 oth | |
| 700 | 1 | |a Wagstaff, John |4 oth | |
| 700 | 1 | |a Callahan, Margaret K. |4 oth | |
| 700 | 1 | |a Postow, Michael A. |4 oth | |
| 700 | 1 | |a Smylie, Michael |4 oth | |
| 700 | 1 | |a Ferrucci, Pier Francesco |4 oth | |
| 700 | 1 | |a Dummer, Reinhard |4 oth | |
| 700 | 1 | |a Hill, Andrew |4 oth | |
| 700 | 1 | |a Taylor, Fiona |4 oth | |
| 700 | 1 | |a Sabater, Javier |4 oth | |
| 700 | 1 | |a Walker, Dana |4 oth | |
| 700 | 1 | |a Kotapati, Srividya |4 oth | |
| 700 | 1 | |a Abernethy, Amy |4 oth | |
| 700 | 1 | |a Long, Georgina V. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Hamzah, N. ELSEVIER |t The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000241849 |
| 773 | 1 | 8 | |g volume:82 |g year:2017 |g pages:80-91 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2017.05.031 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 82 |j 2017 |h 80-91 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
d s ds |
|---|---|
| matchkey_str |
schadendorfdirklarkinjameswolchokjeddhod:2017----:elheaeqaiyfieeutfotehsii |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
44.52 |
| publishDate |
2017 |
| allfields |
10.1016/j.ejca.2017.05.031 doi GBVA2017016000016.pica (DE-627)ELV020442440 (ELSEVIER)S0959-8049(17)30995-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Schadendorf, Dirk verfasserin aut Health-related quality of life results from the phase III CheckMate 067 study 2017transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma Elsevier Larkin, James oth Wolchok, Jedd oth Hodi, F. Stephen oth Chiarion-Sileni, Vanna oth Gonzalez, Rene oth Rutkowski, Piotr oth Grob, Jean-Jacques oth Cowey, C. Lance oth Lao, Christopher oth Wagstaff, John oth Callahan, Margaret K. oth Postow, Michael A. oth Smylie, Michael oth Ferrucci, Pier Francesco oth Dummer, Reinhard oth Hill, Andrew oth Taylor, Fiona oth Sabater, Javier oth Walker, Dana oth Kotapati, Srividya oth Abernethy, Amy oth Long, Georgina V. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:82 year:2017 pages:80-91 extent:12 https://doi.org/10.1016/j.ejca.2017.05.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 82 2017 80-91 12 045F 610 |
| spelling |
10.1016/j.ejca.2017.05.031 doi GBVA2017016000016.pica (DE-627)ELV020442440 (ELSEVIER)S0959-8049(17)30995-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Schadendorf, Dirk verfasserin aut Health-related quality of life results from the phase III CheckMate 067 study 2017transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma Elsevier Larkin, James oth Wolchok, Jedd oth Hodi, F. Stephen oth Chiarion-Sileni, Vanna oth Gonzalez, Rene oth Rutkowski, Piotr oth Grob, Jean-Jacques oth Cowey, C. Lance oth Lao, Christopher oth Wagstaff, John oth Callahan, Margaret K. oth Postow, Michael A. oth Smylie, Michael oth Ferrucci, Pier Francesco oth Dummer, Reinhard oth Hill, Andrew oth Taylor, Fiona oth Sabater, Javier oth Walker, Dana oth Kotapati, Srividya oth Abernethy, Amy oth Long, Georgina V. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:82 year:2017 pages:80-91 extent:12 https://doi.org/10.1016/j.ejca.2017.05.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 82 2017 80-91 12 045F 610 |
| allfields_unstemmed |
10.1016/j.ejca.2017.05.031 doi GBVA2017016000016.pica (DE-627)ELV020442440 (ELSEVIER)S0959-8049(17)30995-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Schadendorf, Dirk verfasserin aut Health-related quality of life results from the phase III CheckMate 067 study 2017transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma Elsevier Larkin, James oth Wolchok, Jedd oth Hodi, F. Stephen oth Chiarion-Sileni, Vanna oth Gonzalez, Rene oth Rutkowski, Piotr oth Grob, Jean-Jacques oth Cowey, C. Lance oth Lao, Christopher oth Wagstaff, John oth Callahan, Margaret K. oth Postow, Michael A. oth Smylie, Michael oth Ferrucci, Pier Francesco oth Dummer, Reinhard oth Hill, Andrew oth Taylor, Fiona oth Sabater, Javier oth Walker, Dana oth Kotapati, Srividya oth Abernethy, Amy oth Long, Georgina V. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:82 year:2017 pages:80-91 extent:12 https://doi.org/10.1016/j.ejca.2017.05.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 82 2017 80-91 12 045F 610 |
| allfieldsGer |
10.1016/j.ejca.2017.05.031 doi GBVA2017016000016.pica (DE-627)ELV020442440 (ELSEVIER)S0959-8049(17)30995-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Schadendorf, Dirk verfasserin aut Health-related quality of life results from the phase III CheckMate 067 study 2017transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma Elsevier Larkin, James oth Wolchok, Jedd oth Hodi, F. Stephen oth Chiarion-Sileni, Vanna oth Gonzalez, Rene oth Rutkowski, Piotr oth Grob, Jean-Jacques oth Cowey, C. Lance oth Lao, Christopher oth Wagstaff, John oth Callahan, Margaret K. oth Postow, Michael A. oth Smylie, Michael oth Ferrucci, Pier Francesco oth Dummer, Reinhard oth Hill, Andrew oth Taylor, Fiona oth Sabater, Javier oth Walker, Dana oth Kotapati, Srividya oth Abernethy, Amy oth Long, Georgina V. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:82 year:2017 pages:80-91 extent:12 https://doi.org/10.1016/j.ejca.2017.05.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 82 2017 80-91 12 045F 610 |
| allfieldsSound |
10.1016/j.ejca.2017.05.031 doi GBVA2017016000016.pica (DE-627)ELV020442440 (ELSEVIER)S0959-8049(17)30995-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Schadendorf, Dirk verfasserin aut Health-related quality of life results from the phase III CheckMate 067 study 2017transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma Elsevier Larkin, James oth Wolchok, Jedd oth Hodi, F. Stephen oth Chiarion-Sileni, Vanna oth Gonzalez, Rene oth Rutkowski, Piotr oth Grob, Jean-Jacques oth Cowey, C. Lance oth Lao, Christopher oth Wagstaff, John oth Callahan, Margaret K. oth Postow, Michael A. oth Smylie, Michael oth Ferrucci, Pier Francesco oth Dummer, Reinhard oth Hill, Andrew oth Taylor, Fiona oth Sabater, Javier oth Walker, Dana oth Kotapati, Srividya oth Abernethy, Amy oth Long, Georgina V. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:82 year:2017 pages:80-91 extent:12 https://doi.org/10.1016/j.ejca.2017.05.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 82 2017 80-91 12 045F 610 |
| language |
English |
| source |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:82 year:2017 pages:80-91 extent:12 |
| sourceStr |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:82 year:2017 pages:80-91 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Health-related quality of life Checkpoint inhibitors Nivolumab Ipilimumab Advanced melanoma |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| authorswithroles_txt_mv |
Schadendorf, Dirk @@aut@@ Larkin, James @@oth@@ Wolchok, Jedd @@oth@@ Hodi, F. Stephen @@oth@@ Chiarion-Sileni, Vanna @@oth@@ Gonzalez, Rene @@oth@@ Rutkowski, Piotr @@oth@@ Grob, Jean-Jacques @@oth@@ Cowey, C. Lance @@oth@@ Lao, Christopher @@oth@@ Wagstaff, John @@oth@@ Callahan, Margaret K. @@oth@@ Postow, Michael A. @@oth@@ Smylie, Michael @@oth@@ Ferrucci, Pier Francesco @@oth@@ Dummer, Reinhard @@oth@@ Hill, Andrew @@oth@@ Taylor, Fiona @@oth@@ Sabater, Javier @@oth@@ Walker, Dana @@oth@@ Kotapati, Srividya @@oth@@ Abernethy, Amy @@oth@@ Long, Georgina V. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000241849 |
| dewey-sort |
3610 |
| id |
ELV020442440 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV020442440</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625131840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2017.05.031</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017016000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV020442440</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(17)30995-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schadendorf, Dirk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Health-related quality of life results from the phase III CheckMate 067 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health-related quality of life</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Checkpoint inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nivolumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ipilimumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Advanced melanoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larkin, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wolchok, Jedd</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hodi, F. Stephen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiarion-Sileni, Vanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gonzalez, Rene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rutkowski, Piotr</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grob, Jean-Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cowey, C. Lance</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lao, Christopher</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wagstaff, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Callahan, Margaret K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Postow, Michael A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smylie, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrucci, Pier Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dummer, Reinhard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hill, Andrew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taylor, Fiona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabater, Javier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walker, Dana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kotapati, Srividya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abernethy, Amy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Long, Georgina V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:82</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:80-91</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2017.05.031</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">82</subfield><subfield code="j">2017</subfield><subfield code="h">80-91</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Schadendorf, Dirk |
| spellingShingle |
Schadendorf, Dirk ddc 610 bkl 44.52 Elsevier Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma Health-related quality of life results from the phase III CheckMate 067 study |
| authorStr |
Schadendorf, Dirk |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000241849 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.52 bkl Health-related quality of life results from the phase III CheckMate 067 study Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Health-related quality of life Elsevier Checkpoint inhibitors Elsevier Nivolumab Elsevier Ipilimumab Elsevier Advanced melanoma |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j l jl j w jw f s h fs fsh v c s vcs r g rg p r pr j j g jjg c l c cl clc c l cl j w jw m k c mk mkc m a p ma map m s ms p f f pf pff r d rd a h ah f t ft j s js d w dw s k sk a a aa g v l gv gvl |
| hierarchy_parent_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| hierarchy_parent_id |
ELV000241849 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000241849 |
| title |
Health-related quality of life results from the phase III CheckMate 067 study |
| ctrlnum |
(DE-627)ELV020442440 (ELSEVIER)S0959-8049(17)30995-4 |
| title_full |
Health-related quality of life results from the phase III CheckMate 067 study |
| author_sort |
Schadendorf, Dirk |
| journal |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| journalStr |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
80 |
| author_browse |
Schadendorf, Dirk |
| container_volume |
82 |
| physical |
12 |
| class |
610 610 DE-600 610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Schadendorf, Dirk |
| doi_str_mv |
10.1016/j.ejca.2017.05.031 |
| dewey-full |
610 |
| title_sort |
health-related quality of life results from the phase iii checkmate 067 study |
| title_auth |
Health-related quality of life results from the phase III CheckMate 067 study |
| abstract |
Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. |
| abstractGer |
Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. |
| abstract_unstemmed |
Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Health-related quality of life results from the phase III CheckMate 067 study |
| url |
https://doi.org/10.1016/j.ejca.2017.05.031 |
| remote_bool |
true |
| author2 |
Larkin, James Wolchok, Jedd Hodi, F. Stephen Chiarion-Sileni, Vanna Gonzalez, Rene Rutkowski, Piotr Grob, Jean-Jacques Cowey, C. Lance Lao, Christopher Wagstaff, John Callahan, Margaret K. Postow, Michael A. Smylie, Michael Ferrucci, Pier Francesco Dummer, Reinhard Hill, Andrew Taylor, Fiona Sabater, Javier Walker, Dana Kotapati, Srividya Abernethy, Amy Long, Georgina V. |
| author2Str |
Larkin, James Wolchok, Jedd Hodi, F. Stephen Chiarion-Sileni, Vanna Gonzalez, Rene Rutkowski, Piotr Grob, Jean-Jacques Cowey, C. Lance Lao, Christopher Wagstaff, John Callahan, Margaret K. Postow, Michael A. Smylie, Michael Ferrucci, Pier Francesco Dummer, Reinhard Hill, Andrew Taylor, Fiona Sabater, Javier Walker, Dana Kotapati, Srividya Abernethy, Amy Long, Georgina V. |
| ppnlink |
ELV000241849 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ejca.2017.05.031 |
| up_date |
2024-07-06T17:37:01.323Z |
| _version_ |
1803852103104331776 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV020442440</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625131840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2017.05.031</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017016000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV020442440</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(17)30995-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schadendorf, Dirk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Health-related quality of life results from the phase III CheckMate 067 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health-related quality of life</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Checkpoint inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nivolumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ipilimumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Advanced melanoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larkin, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wolchok, Jedd</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hodi, F. Stephen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiarion-Sileni, Vanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gonzalez, Rene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rutkowski, Piotr</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grob, Jean-Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cowey, C. Lance</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lao, Christopher</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wagstaff, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Callahan, Margaret K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Postow, Michael A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smylie, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrucci, Pier Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dummer, Reinhard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hill, Andrew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taylor, Fiona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabater, Javier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walker, Dana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kotapati, Srividya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abernethy, Amy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Long, Georgina V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:82</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:80-91</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2017.05.031</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">82</subfield><subfield code="j">2017</subfield><subfield code="h">80-91</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3991594 |